Marpai (MRAI) Director Vesting: 75,000 RSUs Increase Holdings to 125,000
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025.
Rhea-AI Filing Summary
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.
Positive
- 75,000 RSUs vested on 08/19/2025, increasing the reporting person's direct holdings to 125,000 shares of Class A common stock
- The Form 4 indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c), which provides a clear procedural context for the trade
- Vesting schedule disclosed: 25,000 RSUs at three months, 25,000 at six months, and 25,000 at nine months from grant date
Negative
- None.
Insights
TL;DR: Director received 75,000 RSUs that vested, bringing direct beneficial ownership to 125,000 shares; transaction reported under Rule 10b5-1.
The reported transaction is a routine insider compensation vesting event: 75,000 RSUs vested on 08/19/2025 at a reported acquisition price of $0.00. The filing notes the transaction was made pursuant to a written plan consistent with Rule 10b5-1(c), which reduces timing concerns about opportunistic trading. Post-transaction beneficial ownership is reported as 125,000 shares of Class A common stock. This disclosure is informational for share ownership tracking and compliance monitoring; it does not by itself indicate change in company fundamentals.
TL;DR: Vesting RSUs are standard director compensation; filing complies with Section 16 reporting and notes a 10b5-1 plan condition.
The Form 4 reflects standard disclosure practice for an insider equity award vesting. The schedule of vesting—three equal installments over nine months—is explicitly provided in the explanation. The checkbox indicating a 10b5-1(c) plan suggests the transaction followed a pre-established instruction or plan. From a governance perspective, timely Form 4 disclosure and clarity on vesting schedule support transparency, with no additional governance concerns stated in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Common Stock | 75,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The RSUs vest over a period of nine months as follows: 25,000 RSUs vested on the three month anniversary of the grant date, 25,000 RSUs vesting on the six month anniversary of the grant date and 25,000 RSUs vesting on the nine month anniversary of the grant date.
FAQ
What did Jennifer Calabrese report on the Form 4 for MRAI?
Was the MRAI transaction made under a 10b5-1 plan?
What is the vesting schedule for the RSUs reported by the MRAI director?
When was the Form 4 signed and filed by the reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.